Pro-Dex, Inc. (NASDAQ:PDEX - Get Free Report) Director Raymond E. Cabillot sold 5,151 shares of the business's stock in a transaction on Friday, March 14th. The stock was sold at an average price of $50.00, for a total value of $257,550.00. Following the sale, the director now owns 300,695 shares in the company, valued at $15,034,750. This represents a 1.68 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Pro-Dex Trading Down 0.3 %
Shares of Pro-Dex stock traded down $0.13 during trading on Friday, hitting $48.92. The company's stock had a trading volume of 14,151 shares, compared to its average volume of 21,678. The stock has a market cap of $159.53 million, a price-to-earnings ratio of 24.34 and a beta of 0.68. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.58 and a quick ratio of 1.44. Pro-Dex, Inc. has a 52 week low of $16.84 and a 52 week high of $59.60. The stock has a 50-day moving average price of $39.74 and a two-hundred day moving average price of $38.81.
Pro-Dex (NASDAQ:PDEX - Get Free Report) last released its quarterly earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 EPS for the quarter, beating analysts' consensus estimates of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. Equities research analysts anticipate that Pro-Dex, Inc. will post 2 EPS for the current fiscal year.
Institutional Trading of Pro-Dex
A number of institutional investors and hedge funds have recently added to or reduced their stakes in PDEX. EAM Investors LLC bought a new stake in shares of Pro-Dex in the 4th quarter valued at $1,047,000. O Shaughnessy Asset Management LLC acquired a new position in Pro-Dex in the fourth quarter valued at $995,000. 683 Capital Management LLC bought a new stake in Pro-Dex during the fourth quarter valued at $739,000. Ritholtz Wealth Management bought a new stake in Pro-Dex during the fourth quarter valued at $572,000. Finally, American Century Companies Inc. acquired a new stake in Pro-Dex during the 4th quarter worth about $558,000. Institutional investors and hedge funds own 15.28% of the company's stock.
Wall Street Analyst Weigh In
Separately, StockNews.com downgraded shares of Pro-Dex from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th.
Read Our Latest Stock Report on PDEX
Pro-Dex Company Profile
(
Get Free Report)
Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.
Featured Stories
Before you consider Pro-Dex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pro-Dex wasn't on the list.
While Pro-Dex currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
